ATE354802T1 - Methoden zum screening knochenmorphogenetishemimetika - Google Patents
Methoden zum screening knochenmorphogenetishemimetikaInfo
- Publication number
- ATE354802T1 ATE354802T1 AT00992674T AT00992674T ATE354802T1 AT E354802 T1 ATE354802 T1 AT E354802T1 AT 00992674 T AT00992674 T AT 00992674T AT 00992674 T AT00992674 T AT 00992674T AT E354802 T1 ATE354802 T1 AT E354802T1
- Authority
- AT
- Austria
- Prior art keywords
- methods
- agents
- morphogenetishemimetics
- screening bone
- daf
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 210000000988 bone and bone Anatomy 0.000 title 1
- 238000012216 screening Methods 0.000 title 1
- 101100008648 Caenorhabditis elegans daf-4 gene Proteins 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 102000008131 Bone Morphogenetic Protein 7 Human genes 0.000 abstract 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 abstract 1
- 102000001893 Bone Morphogenetic Protein Receptors Human genes 0.000 abstract 1
- 108010040422 Bone Morphogenetic Protein Receptors Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24623100P | 2000-11-06 | 2000-11-06 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE354802T1 true ATE354802T1 (de) | 2007-03-15 |
Family
ID=22929832
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT00992674T ATE354802T1 (de) | 2000-11-06 | 2000-12-07 | Methoden zum screening knochenmorphogenetishemimetika |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US20040009532A1 (de) |
| EP (1) | EP1334365B1 (de) |
| AT (1) | ATE354802T1 (de) |
| AU (1) | AU2001245209A1 (de) |
| CA (1) | CA2431552A1 (de) |
| DE (1) | DE60033576T2 (de) |
| ES (1) | ES2282163T3 (de) |
| WO (1) | WO2002039118A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2244228A1 (en) * | 1996-01-22 | 1997-07-24 | Creative Biomolecules, Inc. | Morphogen analogs and methods for producing them |
| US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
| WO2003070749A2 (en) | 2002-02-15 | 2003-08-28 | Northwestern University | Self-assembly of peptide-amphiphile nanofibers under physiological conditions |
| AU2003247551C1 (en) | 2002-06-17 | 2010-12-09 | Thrasos Innovation, Inc. | Single domain TDF-related compounds and analogs thereof |
| US7554021B2 (en) | 2002-11-12 | 2009-06-30 | Northwestern University | Composition and method for self-assembly and mineralization of peptide amphiphiles |
| EP2441474B1 (de) | 2003-10-17 | 2015-08-05 | Joslin Diabetes Center, Inc. | Verfahren und Zusammensetzungen zur Modulation der Adipozytfunktion |
| MXPA06006388A (es) | 2003-12-05 | 2006-09-04 | Univ Northwestern | Peptidos anfifilicos de auto-ensamble y metodos relacionados para el suministro del factor de crecimiento. |
| WO2006009836A2 (en) | 2004-06-17 | 2006-01-26 | Thrasos Therapeutics, Inc. | Tdf-related compounds and analogs thereof |
| EP1847265A4 (de) * | 2005-01-26 | 2008-04-30 | Mian Long | Verwendung on flavonol und flavonolglykosiden zur stimulierung des wachstums renal-tubulärer epithelzellen zur sezernierung des nierensezernierenden knochenwachstumsfaktors |
| US20100150885A1 (en) | 2005-06-01 | 2010-06-17 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
| US8299212B2 (en) | 2005-09-20 | 2012-10-30 | Thrasos Therapeutics, Inc. | TDF-related compounds and analogs thereof, analogs and bioactive fragments |
| US8076295B2 (en) | 2007-04-17 | 2011-12-13 | Nanotope, Inc. | Peptide amphiphiles having improved solubility and methods of using same |
| JP2010539932A (ja) * | 2007-09-28 | 2010-12-24 | ストライカー コーポレイション | 骨形成タンパク質に対する中和抗体を検出するための方法 |
| KR20120012811A (ko) | 2009-04-13 | 2012-02-10 | 노오쓰웨스턴 유니버시티 | 신규한 연골 재생용 펩티드-기반 스카폴드 및 이들의 사용 방법 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5567584A (en) * | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| US5650276A (en) * | 1991-03-11 | 1997-07-22 | Creative Biomolecules, Inc. | Morphogenic protein screening method |
| US6071695A (en) * | 1992-02-21 | 2000-06-06 | Creative Biomolecules, Inc. | Methods and products for identification of modulators of osteogenic protein-1 gene expression |
| US6248554B1 (en) * | 1993-11-24 | 2001-06-19 | The Procter & Gamble Company | DNA sequence coding for a BMP receptor |
| EP0756628B1 (de) * | 1994-04-29 | 2007-11-14 | Curis, Inc. | Morphogene protein-spezifische zelloberflächenrezeptoren und ihre verwendungen |
| US5981483A (en) * | 1994-05-04 | 1999-11-09 | Mount Sinai Hospital Corporation | Compositions comprising modulators of cytokines of the TGF-β superfamily |
| US6083690A (en) * | 1995-06-02 | 2000-07-04 | Osteoscreen, Inc. | Methods and compositions for identifying osteogenic agents |
| US6190659B1 (en) * | 1996-09-17 | 2001-02-20 | The Rockefeller University | Bacterial plasmin binding protein and methods of use thereof |
| JP2003527076A (ja) * | 1999-04-09 | 2003-09-16 | ヒューマン ジノーム サイエンシーズ， インコーポレイテッド | 骨形態形成タンパク質 |
-
2000
- 2000-12-07 EP EP00992674A patent/EP1334365B1/de not_active Expired - Lifetime
- 2000-12-07 AU AU2001245209A patent/AU2001245209A1/en not_active Abandoned
- 2000-12-07 AT AT00992674T patent/ATE354802T1/de not_active IP Right Cessation
- 2000-12-07 WO PCT/US2000/042657 patent/WO2002039118A1/en active IP Right Grant
- 2000-12-07 CA CA002431552A patent/CA2431552A1/en not_active Abandoned
- 2000-12-07 DE DE60033576T patent/DE60033576T2/de not_active Expired - Lifetime
- 2000-12-07 ES ES00992674T patent/ES2282163T3/es not_active Expired - Lifetime
-
2003
- 2003-05-05 US US10/429,914 patent/US20040009532A1/en not_active Abandoned
-
2008
- 2008-06-06 US US12/157,075 patent/US20090124537A1/en not_active Abandoned
-
2010
- 2010-09-03 US US12/875,633 patent/US20110081662A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2282163T3 (es) | 2007-10-16 |
| US20110081662A1 (en) | 2011-04-07 |
| US20090124537A1 (en) | 2009-05-14 |
| EP1334365A1 (de) | 2003-08-13 |
| DE60033576T2 (de) | 2007-10-31 |
| WO2002039118A1 (en) | 2002-05-16 |
| US20040009532A1 (en) | 2004-01-15 |
| WO2002039118A8 (en) | 2002-12-27 |
| CA2431552A1 (en) | 2002-05-16 |
| EP1334365B1 (de) | 2007-02-21 |
| DE60033576D1 (de) | 2007-04-05 |
| AU2001245209A1 (en) | 2002-05-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE380187T1 (de) | Agonisten und antagonisten für den lpa-rezeptor und anwendungsmethoden | |
| TR200100267T2 (tr) | İkameli anilid bileşimleri ve yöntemler. | |
| DE60033576D1 (de) | Methoden zum screening knochenmorphogenetishemimetika | |
| NO983431L (no) | Anti-klöemidler | |
| NO20042964L (no) | Spiroazasykliske forbindelser som monoaminreseptormodulatorer | |
| AR038563A1 (es) | Composicion de ziprasidona y controles sinteticos | |
| EP1017713A4 (de) | ZYKLISCHE AGONISTEN UND ANTAGONISTEN DER C5a REZEPTOREN SOWIE G-PROTEIN GEKOPPELTEN REZEPTOREN | |
| ATE349434T1 (de) | Lactamderivaten zur verwendung als humane 11cby rezeptorantagonisten | |
| ATE322258T1 (de) | Methoden und zusammensetzungen zur modulation der aktivität der alpha-adrenergen rezeptoren | |
| ATE288747T1 (de) | Methoden und zusammensetzungen zur modulierung der aktivität von alpha-adrenergen rezeptoren | |
| NO20061845L (no) | Fenyl-piperazinderivater som modulatorer for muskarine reseptorer | |
| AU5301201A (en) | Methods of modulating hair growth | |
| TW200607814A (en) | Cell surface receptor isoforms and methods of identifying and using the same | |
| WO2005117968A3 (en) | Compositions and methods comprising an egfl7 antagonist for modulating vascular development | |
| DE60207514D1 (de) | Zusammensetzungen und Verfahren zum Nachweis und zur Behandlung von mit Chemokinrezeptoren verbundenen Krankheiten | |
| WO2003068944A3 (en) | METHODS AND COMPOSITION FOR MODULATING TYPE I MUSCLE FORMATION USING PGC-1α- | |
| ATE273956T1 (de) | Arylsubstituierte olefinische amine und ihre verwendung als cholinergische rezeptoragonisten | |
| ATE309543T1 (de) | Natürlicher ligand von gpcr chemr23 und dessen verwendung | |
| EA200600440A1 (ru) | 4-((феноксиалкил)тио)еноксиуксусные кислоты и их аналоги | |
| DE69935670D1 (de) | Behandlung von dyskinesie durch mu-selektive opioidantagonisten | |
| EA200700951A1 (ru) | БЕЛКИ, СОДЕРЖАЩИЕ ДОМЕНЫ vWFA И/ИЛИ ANT_IG | |
| YU17503A (sh) | Receptor oblasti (ii) edb-fibronektina | |
| DE59809283D1 (de) | Inhibitoren für den urokinaserezeptor | |
| ATE269085T1 (de) | Verwendung von diltiazem zur behandlung von pathologien der netzhaut | |
| CY1110278T1 (el) | Μεθοδος διαλογης παραγοντων ικανων να θεραπευουν την παχυσαρκια |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1334365 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |